Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Corrigendum to "About the French prohibition of textured breast implants: Is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position" [Breast 46 (August 2019) 95-96].

Cardoso MJ, Biganzoli L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Kovacs T, Wyld L.

Breast. 2019 Dec;48:103. doi: 10.1016/j.breast.2019.10.010. No abstract available.

2.

Corrigendum to "EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants" [Breast 44 (April 2019) 90-93].

Cardoso MJ, Wyld L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Biganzoli L.

Breast. 2019 Dec;48:102. doi: 10.1016/j.breast.2019.10.005. No abstract available.

3.

Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults.

Biganzoli L, McCartney A, Battisti NML.

JAMA Oncol. 2019 Nov 7. doi: 10.1001/jamaoncol.2019.4708. [Epub ahead of print] No abstract available.

PMID:
31697305
4.

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification.

McCartney A, Vignoli A, Tenori L, Fornier M, Rossi L, Risi E, Luchinat C, Biganzoli L, Di Leo A.

NPJ Breast Cancer. 2019 Aug 29;5:26. doi: 10.1038/s41523-019-0123-9. eCollection 2019.

5.

Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM).

Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, Criscitiello C, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S.

Cancers (Basel). 2019 Aug 8;11(8). pii: E1137. doi: 10.3390/cancers11081137.

6.

Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.

Rossi L, McCartney A, Risi E, De Santo I, Migliaccio I, Malorni L, Biganzoli L, Di Leo A.

Clin Breast Cancer. 2019 Jun 11. pii: S1526-8209(19)30307-6. doi: 10.1016/j.clbc.2019.05.019. [Epub ahead of print] Review.

PMID:
31358432
7.

Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution.

Barchiesi G, McCartney A, Biagioni C, Siclari O, Rossi L, Pestrin M, Di Leo A, Biganzoli L.

Breast J. 2019 Nov;25(6):1225-1229. doi: 10.1111/tbj.13437. Epub 2019 Jul 16.

PMID:
31310384
8.

HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology.

Brain E, Caillet P, de Glas N, Biganzoli L, Cheng K, Lago LD, Wildiers H.

J Geriatr Oncol. 2019 Nov;10(6):1003-1013. doi: 10.1016/j.jgo.2019.06.004. Epub 2019 Jun 22. Review.

PMID:
31235436
9.

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, Arpino G, Bernardo A, Martignetti A, Risi E, Pestrin M, Boni L, Benelli M, Biganzoli L, Di Leo A, Malorni L.

Breast Cancer Res. 2019 May 29;21(1):71. doi: 10.1186/s13058-019-1149-5.

10.

About the French prohibition of textured breast implants: is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position.

Cardoso MJ, Biganzoli L, Rubio IT, M L, G C, B C, L M, Kovacs T, Wyld L.

Breast. 2019 Aug;46:95-96. doi: 10.1016/j.breast.2019.05.005. Epub 2019 May 3. No abstract available. Erratum in: Breast. 2019 Dec;48:103.

PMID:
31125932
11.

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL; “Metronomic Chemotherapy in Advanced Breast Cancer” Study Group.

Onco Targets Ther. 2019 Apr 23;12:2989-2997. doi: 10.2147/OTT.S189163. eCollection 2019.

12.

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart M, Gradishar WJ, Chia S, Di Leo A, Malorni L.

Eur J Cancer. 2019 Jun;114:55-66. doi: 10.1016/j.ejca.2019.04.002. Epub 2019 May 3.

PMID:
31059974
13.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J; SOLE Investigators.

Br J Cancer. 2019 May;120(10):959-967. doi: 10.1038/s41416-019-0435-4. Epub 2019 Apr 10.

PMID:
30967649
14.

Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice.

Garcia-Etienne CA, Mansel RE, Tomatis M, Heil J, Biganzoli L, Ferrari A, Marotti L, Sgarella A, Ponti A; EUSOMA Working Group.

Breast. 2019 Jun;45:89-96. doi: 10.1016/j.breast.2019.03.002. Epub 2019 Mar 11.

PMID:
30925382
15.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.

PMID:
30765258
16.

The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.

Rossi L, McCartney A, De Santo I, Risi E, Moretti E, Malorni L, Biganzoli L, Di Leo A.

Cancer Treat Rev. 2019 Mar;74:29-34. doi: 10.1016/j.ctrv.2019.01.007. Epub 2019 Jan 25. Review.

PMID:
30708267
17.

EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants.

Cardoso MJ, Wyld L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Biganzoli L.

Breast. 2019 Apr;44:90-93. doi: 10.1016/j.breast.2019.01.011. Epub 2019 Jan 26. Erratum in: Breast. 2019 Dec;48:102.

PMID:
30703669
18.

Variability in breast cancer surgery training across Europe: An ESSO-EUSOMA international survey.

Rubio IT, Wyld L, Esgueva A, Kovacs T, Cardoso MJ, Leidenius M, Bianca S, Kolacinska A, Marotti L, Lecoq C, Biganzoli L, Audisio R.

Eur J Surg Oncol. 2019 Apr;45(4):567-572. doi: 10.1016/j.ejso.2019.01.003. Epub 2019 Jan 5.

PMID:
30638809
19.

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Rossi L, McCartney A, Risi E, Malorni L, Biganzoli L, Di Leo A.

Ther Adv Med Oncol. 2018 Dec 10;10:1758835918815591. doi: 10.1177/1758835918815591. eCollection 2018.

20.

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.

Leo S, Arnoldi E, Repetto L, Coccorullo Z, Cinieri S, Fedele P, Cazzaniga M, Lorusso V, Latorre A, Campanella G, Ciccarese M, Accettura C, Pisconti S, Rinaldi A, Brunetti C, Raffaele M, Coltelli L, Spazzapan S, Fratino L, Petrucelli L, Biganzoli L.

Oncologist. 2019 Jun;24(6):e232-e240. doi: 10.1634/theoncologist.2017-0676. Epub 2018 Nov 9.

PMID:
30413667
21.

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.

Pelizzari G, Arpino G, Biganzoli L, Cinieri S, De Laurentiis M, Del Mastro L, Di Leo A, Gori S, Guarneri V, Marchetti P, Puglisi F.

BMC Cancer. 2018 Sep 27;18(1):932. doi: 10.1186/s12885-018-4843-2.

22.

Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.

Rossi L, Biagioni C, McCartney A, Moretti E, Pestrin M, Sanna G, Risi E, Malorni L, DI Leo A, Biganzoli L.

Anticancer Res. 2018 Aug;38(8):4839-4845. doi: 10.21873/anticanres.12795.

PMID:
30061257
23.

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP.

Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. No abstract available.

24.

The role of abemaciclib in treatment of advanced breast cancer.

McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, Biganzoli L, Di Leo A.

Ther Adv Med Oncol. 2018 May 31;10:1758835918776925. doi: 10.1177/1758835918776925. eCollection 2018. Review.

25.

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.

Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A.

Ann Oncol. 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214.

26.

Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).

Gori S, Puglisi F, Cinquini M, Pappagallo G, Frassoldati A, Biganzoli L, Cortesi L, Fiorentino A, Angiolini C, Tinterri C, De Censi A, Levaggi A, Del Mastro L.

Eur J Cancer. 2018 Aug;99:9-19. doi: 10.1016/j.ejca.2018.04.006. Epub 2018 Jun 7. Review.

PMID:
29886394
27.

Metabolomics in breast cancer: A decade in review.

McCartney A, Vignoli A, Biganzoli L, Love R, Tenori L, Luchinat C, Di Leo A.

Cancer Treat Rev. 2018 Jun;67:88-96. doi: 10.1016/j.ctrv.2018.04.012. Epub 2018 May 3. Review.

PMID:
29775779
28.

A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.

Risi E, Grilli A, Migliaccio I, Biagioni C, McCartney A, Guarducci C, Bonechi M, Benelli M, Vitale S, Biganzoli L, Bicciato S, Di Leo A, Malorni L.

Breast Cancer Res Treat. 2018 Jul;170(2):329-341. doi: 10.1007/s10549-018-4766-2. Epub 2018 Mar 22.

PMID:
29564743
29.

Nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper.

Mislang AR, Di Donato S, Hubbard J, Krishna L, Mottino G, Bozzetti F, Biganzoli L.

J Geriatr Oncol. 2018 Jul;9(4):382-392. doi: 10.1016/j.jgo.2018.01.003. Epub 2018 Feb 1. Review.

30.

Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer?

Malorni L, Biganzoli L.

Breast Care (Basel). 2017 Oct;12(5):288-289. doi: 10.1159/000484259. Epub 2017 Oct 25. No abstract available.

31.

Quality indicators in breast cancer care: An update from the EUSOMA working group.

Biganzoli L, Marotti L, Hart CD, Cataliotti L, Cutuli B, Kühn T, Mansel RE, Ponti A, Poortmans P, Regitnig P, van der Hage JA, Wengström Y, Rosselli Del Turco M.

Eur J Cancer. 2017 Nov;86:59-81. doi: 10.1016/j.ejca.2017.08.017. Epub 2017 Sep 28. Review.

PMID:
28963914
32.

De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer.

McCartney A, Vignoli A, Hart C, Tenori L, Luchinat C, Biganzoli L, Di Leo A.

Breast. 2017 Aug;34 Suppl 1:S13-S18. doi: 10.1016/j.breast.2017.06.021. Epub 2017 Jul 1.

PMID:
28676389
33.

Controversial issues in the management of older adults with early breast cancer.

Mislang AR, Cheung KL, Hamaker ME, Kunkler I, Markopoulos C, Orecchia R, Brain E, Biganzoli L.

J Geriatr Oncol. 2017 Nov;8(6):397-402. doi: 10.1016/j.jgo.2017.05.004. Epub 2017 Jun 9. Review.

PMID:
28602710
34.

Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations.

Mislang AR, Wildes TM, Kanesvaran R, Baldini C, Holmes HM, Nightingale G, Coolbrandt A, Biganzoli L.

Cancer Treat Rev. 2017 Jun;57:58-66. doi: 10.1016/j.ctrv.2017.05.002. Epub 2017 May 15. Review.

PMID:
28550714
35.

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients.

Chow LWC, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, Huang CS, Lu YS, Zhu L, Chow CYC, Loo WTY, Glück S, Toi M.

Asia Pac J Clin Oncol. 2017 Dec;13(6):372-378. doi: 10.1111/ajco.12682. Epub 2017 Mar 28.

PMID:
28371190
36.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Dec 1;28(12):3111. doi: 10.1093/annonc/mdx036. No abstract available.

37.

No pain, no gain… What we can learn from a trial reporting negative results.

Di Leo A, Risi E, Biganzoli L.

Ann Oncol. 2017 Apr 1;28(4):678-680. doi: 10.1093/annonc/mdx065. No abstract available.

PMID:
28327956
38.

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.

Tryfonidis K, Marreaud S, Khaled H, De Valk B, Vermorken J, Welnicka-Jaskiewicz M, Aalders K, Bartlett JMS, Biganzoli L, Bogaerts J, Cameron D; EORTC- Breast Cancer Group.

Breast Cancer Res Treat. 2017 Jun;163(3):507-515. doi: 10.1007/s10549-017-4203-y. Epub 2017 Mar 21.

PMID:
28324265
39.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. No abstract available. Erratum in: Ann Oncol. 2017 Dec 1;28(12 ):3111.

40.

Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools.

Biganzoli L, Mislang AR, Di Donato S, Becheri D, Biagioni C, Vitale S, Sanna G, Zafarana E, Gabellini S, Del Monte F, Mori E, Pozzessere D, Brunello A, Luciani A, Laera L, Boni L, Di Leo A, Mottino G.

J Gerontol A Biol Sci Med Sci. 2017 Jul 1;72(7):922-928. doi: 10.1093/gerona/glw234.

PMID:
28158486
41.

Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Breast. 2017 Apr;32:269-270. doi: 10.1016/j.breast.2017.01.001. Epub 2017 Jan 18. No abstract available.

PMID:
28109648
42.

Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.

Hart CD, Vignoli A, Tenori L, Uy GL, Van To T, Adebamowo C, Hossain SM, Biganzoli L, Risi E, Love RR, Luchinat C, Di Leo A.

Clin Cancer Res. 2017 Mar 15;23(6):1422-1431. doi: 10.1158/1078-0432.CCR-16-1153. Epub 2017 Jan 12.

43.

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Breast. 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5. No abstract available. Erratum in: Breast. 2017 Apr;32:269-270.

44.

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.

Kong A, Rea D, Ahmed S, Beck JT, López López R, Biganzoli L, Armstrong AC, Aglietta M, Alba E, Campone M, Hsu Schmitz SF, Lefebvre C, Akimov M, Lee SC.

Oncotarget. 2016 Jun 21;7(25):37680-37692. doi: 10.18632/oncotarget.8974.

45.

Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.

Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E.

Cancer Treat Rev. 2016 Feb;43:19-26. doi: 10.1016/j.ctrv.2015.11.009. Epub 2015 Dec 15. Review.

PMID:
26827689
46.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R, Zamagni C, Latorre A, Bruzzese D, Riccardi F, De Laurentiis M, Beano A, Biganzoli L, Zaniboni A, Laudadio L, Malagoli M, Bilancia D, Schettini F, Giuliano M, Cazzaniga ME, De Placido S.

J Cancer Res Clin Oncol. 2016 Mar;142(3):669-78. doi: 10.1007/s00432-015-2033-z. Epub 2015 Aug 25.

PMID:
26531187
47.

Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG).

Biganzoli L, Lichtman S, Michel JP, Papamichael D, Quoix E, Walko C, Aapro M.

Eur J Cancer. 2015 Nov;51(17):2491-500. doi: 10.1016/j.ejca.2015.08.005. Epub 2015 Sep 1. Review.

PMID:
26340809
48.

Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes.

Hart CD, Sanna G, Siclari O, Biganzoli L, Di Leo A.

Breast. 2015 Nov;24 Suppl 2:S136-42. doi: 10.1016/j.breast.2015.07.033. Epub 2015 Aug 29. Review.

PMID:
26320761
49.

Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?

Mislang AR, Biganzoli L.

Cancers (Basel). 2015 Jul 3;7(3):1191-214. doi: 10.3390/cancers7030833. Review.

50.

Continued value of adjuvant anthracyclines as treatment for early breast cancer.

Turner N, Biganzoli L, Di Leo A.

Lancet Oncol. 2015 Jul;16(7):e362-9. doi: 10.1016/S1470-2045(15)00079-0. Review.

PMID:
26149888

Supplemental Content

Loading ...
Support Center